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Abstract
Background: The present study was to investigate the effects and mechanism of Luteolin on myocardial infarct size, cardiac
function and cardiomyocyte apoptosis in diabetic rats with myocardial ischemia/reperfusion (I/R) injury.
Methodology/Principal Findings: Diabetic rats underwent 30 minutes of ischemia followed by 3 h of reperfusion. Animals
were pretreated with or without Luteolin before coronary artery ligation. The severity of myocardial I/R induced LDH release,
arrhythmia, infarct size, cardiac function impairment, cardiomyocyte apoptosis were compared. Western blot analysis was
performed to elucidate the target proteins of Luteolin. The inflammatory cytokine production were also examined in
ischemic myocardium underwent I/R injury. Our results revealed that Luteolin administration significantly reduced LDH
release, decreased the incidence of arrhythmia, attenuated myocardial infarct size, enhanced left ventricular ejection
fraction and decreased myocardial apoptotic death compared with I/R group. Western blot analysis showed that Luteolin
treatment up-regulated anti-apoptotic proteins FGFR2 and LIF expression, increased BAD phosphorylation while decreased
the ratio of Bax to Bcl-2. Luteolin treatment also inhibited MPO expression and inflammatory cytokine production including
IL-6, IL-1a and TNF-a. Moreover, co-administration of wortmannin and Luteolin abolished the beneficial effects of Luteolin.
Conclusions/Significance: This study indicates that Luteolin preserves cardiac function, reduces infarct size and
cardiomyocyte apoptotic rate after I/R injury in diabetic rats. Luteolin exerts its action by up-regulating of anti-apoptotic
proteins FGFR2 and LIF expression, activating PI3K/Akt pathway while increasing BAD phosphorylation and decreasing ratio
of Bax to Bcl-2.
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Introduction
The worldwide epidemic of diabetes mellitus is increasing the
burden of cardiovascular disease, the leading cause of death
among patients with diabetes [1]. Diabetes is now considered to be
a risk equivalent of coronary artery disease for future MI and
cardiovascular death [2]. Our previous study has shown that
diabetes renders the heart more sensitive to I/R injury [3]. This
warrants the significance of aggressive primary prevention against
ischemia/reperfusion (I/R) injury in diabetic patients.
Diabetes is associated with significantly increased cardiomyo-
cyte apoptosis [4,5,6,7]. It is well documented that blocking the
apoptosis process could prevent the loss of contractile cells,
minimize cardiac I/R injury and therefore slow down the
occurrence of heart failure [8]. FGFR2 and LIF are anti-apoptotic
proteins which have been shown to be survival signal mediators in
cardiomyocyte response against myocardial infarction [9,10,11].
Protective effects of LIF and FGFR2 were also related to up-
regulation of the Akt Signaling [9,10,11]. Akt is known to regulate
many survival pathways of the cardiac cells. Activation of Akt
plays a pivotal role in fundamental cellular functions such as cell
proliferation and survival by phosphorylating a variety of
substrates. It has been reported that PI3K/Akt pathway regulates
cardiac contractility and cardiomyocyte apoptosis [12]. Activation
of PI3K/Akt pathway is an effective way to reduce cardiomyocyte
apoptosis thus reduces cardiac I/R injury.
Luteolin, a flavonoid polyphenolic compound, is a widely
distributed in many fruits and vegetables [13]. Studies in human
beings as well as animal models have revealed the diverse
beneficial effects of Luteolin, such as cardiovascular protection,
antioxidant, anti-inflammatory, which suggest Luteolin is a
valuable compound for many medical applications [14,15,16].
Luteolin has been shown to improve contractile function and
attenuates apoptosis following I/R injury in adult rat cardiomy-
ocytes [17]. In addition, Luteolin significantly enhanced left
ventricular pressure and the global and relative coronary flow in
Langendorff rabbit hearts subjected to repeated myocardial
ischemia [18]. The potential effects of Luteolin on diabetes and
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exerting protection effects during cardiac I/R injury in diabetic
rats and the underlying mechanism responsible for its effects.
Therefore, the aims of the present study were 1) to clarify
whether Luteolin protects diabetic rats from cardiac I/R injury
and cardiomyocytes apoptosis; 2) to identify the underlying
mechanisms of Luteolin on I/R injury and cardiomyocytes
apoptosis in diabetic rats.
Methods
Animals
The experiments were performed in adherence with the
National Institutes of Health Guidelines on the Use of Laboratory
Animals and were approved by the Fourth Military Medical
University Ethic Committee on Animal Care (Approval ID:
2009055). One hundred and fifty adult male Sprague-Dawley (SD)
rats, weight 200 to 220 g were purchased from the animal center
in the Fourth Military Medical University. Diabetes mellitus (DM)
was induced by intraperitoneal injections (i.p.) of STZ (50 mg/kg,
STZ was dissolved in 0.1 M citrate buffer, pH 4.5) as previously
described [19]. Rats were randomly allocated into the following
groups with n=30 each: (1) Non-DM+sham group (Non-DM); (2)
DM+sham group (Sham)(Diabetic group); (3) DM+I/R group (I/
R); (4) DM+Luteolin+I/R group (Luteolin); (5) DM+Luteolin+-
wortmannin group+I/R (Luteolin+W).
Blood glucose concentration was determined by using a
reflectance meter (Accu-Chek, Roche Diagnostics GmbH, Mann-
heim, Germany) 1 week after STZ injection. Random blood
glucose was tested in each rat for three times, all of these three
values $16.7 mmol/L was considered as a cutoff point for
diabetes. Blood glucose testing was also repeated at 3 and 8weeks
after STZ injection. Eight weeks after STZ administration,
Luteolin (10 mg/kg) (99%, Sigma, USA) was given by tail vein
injection for three days. Wortmannin (a specific PI3K inhibitor,
16 mg/kg) was injected via the tail vein 5 min before Luteolin
injection (Luteolin and Wortmannin were both dissolved in
DMSO). Sham group received the same volume of DMSO for
three days.
LDH release evaluation
Myocardial cellular damage was evaluated by measuring lactate
dehydrogenase (LDH) activity in plasma. LDH released from
ischemic tissue was determined from arterial blood drawn from the
carotid catheter 3 h after reperfusion. LDH activity was measured
spectrophotometrically with a commercially available assay kit
(Sigma, St Louis, MO, USA).
Construction of I/R injury animal model and
hemodynamic evaluation
I/R injury animal model was constructed by LAD ligation for
30 min followed by 3 h reperfusion eight weeks after STZ
injection as previous described [3]. In brief, rats were anesthetized
with 3% isoflurane. The chest was opened through a left thoracic
incision. A 6–0 silk suture slipknot was placed at the distal 1/3 of
the left anterior descending artery. The left ventricular pressure
(LVP) was measured via a Millar Mikro-tip catheter transducer
that was inserted into the left ventricular cavity through the left
carotid artery. After 30 min of ischemia, the slipknot was released,
and the myocardium was reperfused for 3 h. Sham operated
control rats underwent the same surgical procedures except that
the suture placed under the left coronary artery was not tied.
Cardiac function was continuously determined by invasive
hemodynamic evaluation methods during the entire I/R period.
The first derivative of the left ventricular pressure (+dp/dt max
and 2dp/dt max), heart rate (HR), blood pressure (BP), and
Electrocardiogram (ECG) were obtained by use of computer
algorithms and an interactive videographics program (Po-Ne-Mah
Physiology Platform P3 Plus, Gould Instrument Systems, Valley
View, Ohio). Premature ventricular beats (PVB), ventricular
tachycardia (VT) and ventricular fibrillation (VF) were evaluated
according to the diagnostic criteria advocated by the Lambeth
Convention [20].
Measurement of Myocardial Infarct Size
Myocardial Infarct Size was evaluated by Evans Blue/TTC
staining as previously described [3]. Three hours after reperfusion,
the ligature around the coronary artery was retied, and 1 ml of 2%
Evans Blue dye was injected into the side arm of the aortic
cannula. The heart was quickly excised after the dye was
uniformly distributed, frozen at 280uC and sliced transversally
into 1 mm thick sections. The slices were incubated in 1% 2, 3, 5-
triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St Louis, Mo)
for 10 min at 37uC. Evans blue stained areas indicated area-not-
at-risk (ANAR). Red parts in the heart, which were stained by
TTC, represented for ischemic but viable tissue. Staining negative
areas indicated infarcted myocardium. Areas of infarct size (IS)
and area-at-risk (AAR) were measured digitally using Image Pro
Plus software (Media Cybernetics). IS and AAR were expressed as
percentages of the left ventricular area (IS/LV and AAR/LV
respectively).
Determination of Myocardial Apoptosis
Myocardial apoptosis was determined by terminal deoxynu-
cleotidyl transferase-mediated dUTP-biotin nick end labeling
(TUNEL) staining and caspase 3 activity assay as previously
described [3]. TUNEL staining was performed with fluorescein-
dUTP (In Situ Cell Death Detection Kit; Roche Diagnostics) for
apoptotic cell nuclei and 49,6-diamidino-2-phenylindole (DAPI)
(Sigma) stained all cell nuclei. Additional staining was performed
using a monoclonal antibody against Troponin I (cTnI, Santa
Cruz) for the identification of myocardium. Apoptotic index (AI)
was determined. AI=number of TUNEL-positive myocytes/total
number of myocytes stained with DAPI from a total of 40 fields
per heart (n=5). All of these assays were performed in a blinded
manner. Caspase-3 activity was measured with the ApoAlert
Caspase-3 Assay Plate (Clontech, Mountain View, Calif) accord-
ing to the manufacturer’s instructions [21]. Substrate cleavage was
monitored fluorometrically with a SpectraMax Gemini spectro-
photometer (Molecular Devices) with excitation and emission
wavelengths of 350 and 450 nm.
Determination of Cardiac Function
Echocardiography was conducted at 24 h after infarction as
previously described [19]. Sedated rats (3% isoflurane) were
studied on an echocardiography system (Sequoia Acuson,
Siemens; 15-MHz linear transducer). Cardiac dimensions and
function were assessed by M-mode echocardiography. Left
ventricular end-diastolic diameter (LVEDD) and Left ventricular
end-systolic diameter (LVESD) were measured on the parasternal
left ventricular long axis view. All measurements represent the
mean of 5 consecutive cardiac cycles. Left ventricular end-systolic
volume (LVESV), Left ventricular end-diastolic volume (LVEDV)
and Left ventricular ejection fraction (LVEF) were calculated by
use of computer algorithms. All of these measurements were
performed in a blinded manner.
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Protein was isolated from homogenized heart tissue with Trizol
reagent (Invitrogen, Carlsbad, Calif) and standard Invitrogen
protocols. After protein concentration quantitation with the
modified Bradford assay (Bio-Rad Laboratories, Hercules, Calif),
protein was then used for Western blotting with primary
antibodies against caspase-3, cleaved caspase-3, FGFR2, LIF,
Akt, Akt-P (Thr 308, Ser 473), BAD, BAD-P (Ser 136), Bax, Bcl-2
(Santa Cruz Biotechnology, Santa Cruz, Calif). The blots were
visualized with a chemiluminescene system (Amersham Biosci-
ence, Buchinghamshire, UK). The signals were quantified by
Image Pro Plus software (Media Cybernetics).
Determination of tissue myeloperoxidase (MPO),
interleukin-6 (IL-6), IL-1a and tumor necrosis factor-alpha
(TNF-a) activity
Following the 3 h reperfusion period, tissue sample were taken
from the AAR zones for MPO activity analysis. The activity of
MPO was measured spectrophotometrically at 460 nm and
expressed as units per 100 mg of tissue. The concentrations of
IL-6, IL-1a and TNF-a were measured by enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer’s
instructions as previously described [3]. Values are expressed as
pg/mg of total protein.
Statistical analysis
Continuous variables that approximated the normal distribution
were expressed as means 6 SD. Comparison between groups were
subjected to ANOVA followed by Bonferroni correction for post
hoc t-test. Data expressed as proportions were assessed with a Chi-
square test. Two sided tests have been used throughout, and P
values,0.05 were considered statistically significant. SPSS soft-
ware package version 14.0 (SPSS, Chicago, IL) was used for data
analysis.
Results
Baseline parameters
No major differences were found between groups in terms of
heart rate and blood pressure before the I/R injury. Blood glucose
and the heart to body mass ratio were significantly higher in the
diabetic group as compared with the non-diabetic group. Body
mass were lower in the diabetic group as compared with the non-
diabetic group (Table 1).
Luteolin reduces arrhythmia and LDH release after I/R
injury in diabetic rats
Luteolin administration significantly decreased the release of
lactate dehydrogenase (LDH), a biochemical marker for necrotic
cell death, as compared with the I/R group (116.6619.9 vs
161.6612.1, P=0.003). However, the PI3K inhibitor wortmannin
pretreatment statistically increased the release of LDH compared
with the Luteolin group (153.468.9 vs 116.6619.9, P=0.005)
(Figure 1a). I/R injury induced frequent attacks of premature
ventricular beats (PVB), ventricular tachycardia (VT) and
ventricular fibrillation (VF). Luteolin significantly decreased the
incidence of PVB (33.3% vs 70%, P=0.009), VT (16.7% vs 50%,
P=0.013) and VF (3.3% vs 30%, P=0.012) as compared with the
I/R group. Moreover, wortmannin abolished the anti-arrhythmia
effects of Luteolin (PVB: 63.3% vs 33.3%, P=0.038; VT 43.3% vs
16.7%, P=0.047; VF 26.7% vs 3.3%, P=0.026) as compared with
the Luteolin group (Figure 1b).
Luteolin decreases infarct size after I/R injury in diabetic
rats
Representative images of infarct size as stained by Evans Blue
and TTC were shown in Figure 2a. Luteolin administration
significantly decreased infarct size at 3 h (0.19960.016 vs
0.30460.017, P,0.001) after I/R injury compared with the I/R
group. This effect was abolished by wortmannin treatment
(0.28560.038 in wortmannin group vs 0.19960.016 in Luteolin
group, P=0.002) (Figure 2b). No significant difference in risk area
was found between the four groups (Figure 2c).
Luteolin enhances left ventricular function after I/R injury
Hemodynamic measurements were performed 3 h after I/R
injury (Figure 3a, 3b). Diabetes significantly decreased the 6LV
dp/dt max compared with the non-diabetic group (Figure 3a, 3b).
The +LV dp/dt max (3710.2672.5 vs 4284.6690.6 mmHg/s,
P,0.001) and the 2LV dp/dt max (3920.46152.2 vs
4920.86231.2 mmHg/s, P,0.001) were decreased after I/R
injury in diabetic rats compared with the sham group. Luteolin
significantly enhanced the +LV dp/dt max (4115.06210.3 vs
3710.2672.5 mmHg/s, P=0.004) and the 2LV dp/dt max
(4592.86150.5 vs 3920.46152.2 mmHg/s, P,0.001) compared
with the I/R group. The PI3K inhibitor wortmannin abolished
the effects of Luteolin on the +LV dp/dt max (3813.26101.1 vs
4115.06210.3 mmHg/s, P=0.020) and the 2LV dp/dt max
(4123.86155.0 vs 4592.86150.5 mmHg/s, P=0.001).
Table 1. Basic Parameters of the Rats.
Basic Parameters Non-DM Sham I/R Luteolin Luteolin+W P
(n=30) (n=30) (n=30) (n=30) (n=30)
Heart rate (min
21) 430.1621.7 432.5622.6 427.1619.8 435.9624.4 423.7618.2 0.47
Blood glucose (mmol/L) 4.960.5 22.662.7 23.161.4 22.162.5 24.362.7 ,0.001
Blood pressure (mmHg) 82.363.9 83.264.6 80.963.5 85.664.7 84.962.8 0.39
Body mass (g) 443.9642.6 406.5636.7 398.2628.5 412.8635.9 409.1633.2 ,0.001
Heart to body
mass ratio (mg/g)
1.9660.19 2.1760.12 2.2360.18 2.2160.25 2.1460.28 ,0.001
Values are presented as mean 6 SD.
doi:10.1371/journal.pone.0033491.t001
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after I/R injury (Figure 3c, 3d, 3e). Diabetes decreased LVEF
compared with the non-diabetic group (Figure 3c). Luteolin
administration significantly enhanced LVEF as compared with
the I/R group (0.76160.047 vs 0.67160.028, P=0.006) and
the wortmannin group (0.76160.047 vs 0.66960.063,
P=0.031). Luteolin significantly inhibited the increase of LVESV
compared with the I/R group (0.25260.058 vs 0.39460.018 ml,
Figure 1. Luteolin reduces LDH release and I/R induced arrhythmia in diabetic rats. Diabetes increased LDH release compared with the
non-diabetic group. Luteolin reduced the LDH release after I/R injury in diabetic mice. The PI3K inhibitor wortmannin pretreatment statistically
increased the release of LDH compared with the Luteolin group (a). Luteolin decreased the incidence of PVB, VT and VF attacks as compared with the
I/R group. Wortmannin abolished the anti-arrhythmia effects of Luteolin (b). PVB: premature ventricular beats; VT: ventricular tachycardia; VF,
ventricular fibrillation. The columns and errors bars represent means and SD. *p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g001
Figure 2. Luteolin decreases infarct size in diabetic rats subjected to I/R injury. Representative illustrations of infarct size as stained by
Evans Blue and TTC (a). Luteolin decreased infarct size 3 h after I/R injury compared with the I/R group and the wortmannin group (b). The risk of area
had no statistical difference between the groups (c). The columns and errors bars represent means and SD. *p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g002
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0.38660.036 ml, P=0.002). Luteolin also decreased LVEDV
changes as compared with the I/R group (1.0760.26 vs
1.2060.13 ml, P=0.046) and the wortmannin group
(1.0760.26 vs 1.2060.24 ml, P=0.045).
Luteolin increases antiapoptotic protein expression and
inhibites cardiomyocytes apoptosis after I/R injury in
diabetic rats
The apoptotic rates were significantly higher in the diabetic
group compared with the non-diabetic group. Diabetes enhanced
Figure 3. Luteolin enhances left ventricular function evaluated by hemodynamic measurements and echocardiograpy.
Hemodynamic measurements indicated that diabetes decreased the 6 LV dp/dt max compared with the non-diabetic group. I/R induced
significant decrease of 6 LV dp/dt max in diabetic rats. Luteolin enhanced the 6 LV dp/dt max compared with the I/R group. The PI3K inhibitor
wortmannin abolished the effects of Luteolin on the 6 LV dp/dt max (a, b). Luteolin administration significantly enhanced LVEF as compared with the
I/R group and the wortmannin group (c). Luteolin significantly inhibited the increase of LVESV and LVEDV compared with the I/R group and the
wortmannin group (d, e). LVEF: Left ventricular ejection fraction; LVESV: Left ventricular end-systolic volume; LVEDV: Left ventricular end-diastolic
volume. The columns and errors bars represent means and SD. *p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g003
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non-diabetic group (Figure 4). Representative photomicrograph
showed that TUNEL-positive cardiomyocytes were more fre-
quently observed in the I/R group and the wortmannin group as
compared with the Luteolin group (Figure 4a). Quantitative
analyses demonstrated that the number of TUNEL-positive
cardiomyocytes was significantly less in the Luteolin group than
in the I/R group (0.14660.018 vs 0.2060.03, P=0.009) and the
wortmannin group (0.14660.018 vs 0.19760.047, P=0.032)
(Figure 4b). Concurrently, Luteolin group showed significantly
decreased caspase-3 enzymatic activity compared with the I/R
group (80.868.3 vs 133.2615.3, P,0.001) and the wortmannin
Figure 4. Luteolin decreases cardiomyocytes apoptosis in diabetic rats with I/R Injury. Representative photomicrograph showed that
TUNEL-positive cardiomyocytes were more frequently observed in the I/R group and the wortmannin group compared with the Luteolin group (a).
The apoptotic rate was higher in the diabetic group compared with the diabetic group. The number of TUNEL-positive cardiomyocytes (in green,
DAPI in blue) was significantly reduced in the Luteolin group than in the I/R group and the wortmannin group (b). Luteolin treatment also
significantly decreased caspase-3 activity compared with the I/R group and the wortmannin group (c). Luteolin decreased caspase-3 and cleaved
caspase-3 expression as compared with the I/R group and the wortmannin group (d, e).Scale bar: 25 ı `m. The columns and errors bars represent means
and SD. *p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g004
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blot analysis also demonstrated decreased caspase-3 and cleaved
caspase-3 expression in the Luteolin group as compared with the
I/R group and the wortmannin group (Figure 4d, 4e).
Western blot analysis revealed that the expression of anti-
apoptotic proteins FGFR2 and LIF were decreased in the diabetic
group as compared with the non-diabetic group. Diabetes
decreased p308-Akt, p473-Akt, p136-BAD, Bcl-2 expression and
Bax/Bcl-2 ratio, increased the expression of Bax as compared with
the non-diabetic group (Figure 5). After 3 h of reperfusion,
Luteolin treatment was associated with a significant increase in the
expression of FGFR2 and LIF as compared with the I/R group
(Figure 5a, 5b). Luteolin pretreatment also enhanced phosphor-
ylation of Akt and BAD, decreased Bax expression while increased
Bcl-2 expression resulted in decreased Bax/Bcl-2 ratio in cardiac
tissue that were exposed to I/R injury (5c, 5d, 5e). Interestingly,
the PI3K inhibitor wortmannin abolished the effects of Luteolin
on anti-apoptotic proteins expression. Wortmannin administration
was associated with reduced expression of FGFR2, LIF, p308-Akt,
p473-Akt, Bcl-2 and increased expression of p136-BAD and Bax
as indicated in Figure 5.
Luteolin treatment alleviates leukocyte infiltration and
reduces cytokine levels after I/R injury in diabetic rats
MPO activity was increased in the diabetic group as compared
with the non-diabetic group. Following 3 h of reperfusion, the
activity of MPO was significantly elevated in the I/R group when
compared to the sham group (25.463.5 vs 8.460.6 U/100 mg,
P,0.001). Treatment with Luteolin reduced the MPO activity
compared with the I/R group (18.361.6 vs 25.463.5 U/100 mg,
P=0.003) and the wortmannin group (18.361.6 vs 22.162.3 U/
100 mg, P=0.016) (Figure 6a).
Elisa analysis demonstrated that diabetes increased the levels of
left ventricular IL-6, IL-1a and tumor necrosis factor-a (TNF-a)a s
compared with the non-diabetic group (Figure 6b, 6c, 6d). I/R
resulted in a noticeable increase in IL-6 (40.662.5 vs
23.962.8 pg/mg protein, P,0.001), IL-1a (70.465.9 vs
30.066.1 pg/mg protein, P,0.001) and TNF-a (115.169.0 vs
38.662.8 pg/mg protein, P,0.001) compared with the sham
group. Luteolin reduced the levels of IL-6 (29.963.3 vs
40.662.5 pg/mg protein, P,0.001), IL-1a (40.264.4 vs
70.465.9 pg/mg protein, P,0.001) and TNF-a (55.964.8 vs
115.169.0 pg/mg protein, P,0.001) compared with the I/R
group. Moreover, wortmannin administration significantly in-
creased IL-6 (37.162.1 vs 29.963.3 pg/mg protein, P=0.003),
IL-1a (66.066.5 vs 40.264.4 pg/mg protein, P,0.001) and TNF-
a (94.7613.4 vs 55.964.8 pg/mg protein, P,0.001) production
compared with the Luteolin group.
Discussion
Coronary artery disease is associated with a less favorable
outcome in diabetic than in non-diabetic patients. Accumulating
Figure 5. Western blot analysis. Western blot analysis revealed that Luteolin treatment increased the expression of antiapoptotic proteins FGFR2
and LIF as compared with the I/R group and wortmannin group (a, b). Luteolin also enhanced phosphorylation of Akt and BAD, increased Bax
expression while decreased Bcl-2 expression resulted in decreased Bax/Bcl-2 ratio in cardiac tissue that were exposed to I/R injury (c, d, e). The PI3K
inhibitor wortmannin abolished the effects of Luteolin on antiapoptotic proteins expression. The columns and errors bars represent means and SD.
*p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g005
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increased risk of CHD mortality compared with patients without
diabetes [3,22]. The flavone Luteolin, is widely distributed in
many fruits, vegetables and traditional Chinese herbs [14]. Several
pieces of evidences have shown that Luteolin is capable of
protecting the myocardium against IR injury [23]. Clinical
observations showed that regular Luteolin intake was associated
with a reduced risk of cardiovascular diseases [24]. The beneficial
effects were further supported by experimental studies in rabbit or
guinea pig hearts showing enhancement of left ventricular pressure
and coronary flow by Luteolin with or without regional ischemia
[18,25]. However, the direct cardio-protective effects of Luteolin
on I/R injury in diabetic rats and the exact mechanism of its
therapeutic action are still poorly understood. This promoted an
investigation of the protective effects of Luteolin on I/R injury in
diabetic rats and the underlying mechanism.
The present study has provided the evidence that diabetes
decreased 6 LV dp/dt max, LVEF and caspase-3 expression,
while increased LDH release and cardiomyocyte apoptotic rate.
Luteolin reduced incidence of arrhythmia, reduced LDH
release and decreased infarct size of diabetic rats subjected to I/
R injury. We also demonstrated that Luteolin significantly
improved the left ventricular function via increasing 6 dp/dt
max, LVEF and limiting the increase of LVESV and LVEDV.
Similar to our results, Fang et al [17,26] reported that Luteolin
inhibits apoptosis and improves cardiomyocyte contractile func-
tion in Langendorff perfused rat hearts and isolated cardiomyocyte
subjected to simulated I/R injury.
Cardiomyocyte apoptosis is one of the major contributors to the
development of heart failure after myocardial infarction. Blocking
the apoptosis process could prevent the loss of contractile cells,
minimize cardiac injury induced by I/R injury and therefore slow
down the occurrence of heart failure [8,27]. Given the markedly
improved recovery of left ventricular function exerted by Luteolin,
we determined the effects of Luteolin on post-ischemic cellular
damage. The extent of necrotic and apoptotic cell death was
examined. The release of lactate dehydrogenase (LDH), a
biochemical marker for necrotic cell death, was significantly
decreased in the Luteolin treatment group. Luteolin administra-
tion significantly decreased TUNEL-positive cardiomyocytes and
reduced caspase-3 expression in diabetic rats underwent I/R
injury.
Both FGFR2 and LIF are anti-apoptotic proteins which have
been shown to reduce cardiomyocyte apoptosis in myocardial I/R
Figure 6. Luteolin alleviates leukocyte infiltration and reduces cytokine levels after I/R injury in diabetic rats. Luteolin reduced the
MPO activity compared with the I/R group and the wortmannin group (a). Luteolin reduced the levels of IL-6, IL-1a and TNF-a production compared
with the I/R group and the wortmannin group (b, c, d). The columns and errors bars represent means and SD. *p,0.05 vs Non-DM,
# p,0.05 vs Sham,
1p,0.05 vs Luteolin.
doi:10.1371/journal.pone.0033491.g006
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regulators of physiological and pathological apoptosis. The family
consists of both cell death promoters such as Bax, Bad and cell
death inhibitors, which include Bcl-2, Bcl-X, etc. It has been
demonstrated that the high ratio of Bax/Bcl-2 is associated with
greater vulnerability to apoptotic activation [29,30]. In the present
study, we confirmed that Luteolin may exert its anti-apoptotic
effects through up-regulating FGFR2, LIF expression, increasing
BAD phosphorylation and Bcl-2 expression while down-regulating
Bax expression and decreasing the ratio of Bax to Bcl-2.
It has been reported that PI3K/Akt pathway activation may
lead to BAD phosphorylation and may thereby suppress cell
apoptosis [28]. More interesting, protective effects of LIF and
FGFR2 were also related to up-regulation of the Akt Signaling
[9,10,11]. Hence, we next examined whether the Akt signaling
was activated in diabetic rat hearts subjected to I/R injury. The
specific PI3K inhibitor wortmannin was employed to observe the
effects of co-administration of wortmannin and Luteolin compared
with Luteolin alone. Co-administration of wortmannin and
Luteolin increased infarct size, worsened left ventricular function,
enhanced cardiomyocytes apoptosis, decreased anti-apoptotic
proteins FGFR2 and LIF expression, and associated with
increased ratio of Bax to Bcl-2. These results indicated that
wortmannin can abolish the cardiac protective effects of Luteolin.
The cardio-protective and anti-apoptotic effects of Luteolin were
associated with, at least in part, the activation of PI3K/Akt-
pathway.
Proinflammatory cytokines such as tumor necrosis factor-a
(TNF-a), IL-6 and IL-1a have emerged as significant contributors
to myocardial dysfunction [31]. Xagorari reported that Luteolin
effectively inhibited the lipopolysaccharide-induced TNF-a and
IL-6 production in an activated macrophage-like cell line [32]. In
the present study, we also found that Luteolin inhibited
inflammatory cytokine production including IL-6, IL-1a and
TNF-a. Extracellular MPO can be determined as an index of
polymorphonuclear leukocyte infiltration in response to inflam-
mation. Luteolin administration significantly decreased MPO
expression compared with the I/R group. Co-administration of
wortmannin and Luteolin could also increase the expression of
MPO, IL-6, IL-1a and TNF-a indicating that wortmannin
abolishes the anti-inflammatory effects of Luteolin.
In conclusion, the salient finding of the present study is that
Luteolin pretreatment reduces infarct size and improves cardiac
hemodynamics after I/R injury in diabetic rats. This was through
decreased cardiac apoptosis and inflammation. Luteolin exerted its
protective effects by up-regulating of anti-apoptotic proteins
FGFR2 and LIF expression, which activated PI3K/Akt pathway
and associated with increased BAD phosphorylation and
decreased ratio of Bax to Bcl-2. The present study may provide
important insights for the understanding of the molecular
mechanisms involved in the cardioprotective effect of Luteolin in
diabetic rats underwent I/R injury.
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